March 3, 2012 -- Shaanxi Bicon Pharma raised $250 million from private equity fund PAG Asia Capital; MBK Partners, a PE group based in Korea, sold its 77% interest in Luye Pharma Group to three other PE firms; C3 Jian, a dental spinoff from UCLA with a China subsidiary, announced a new $30 million funding round; Shijiazhuang Yiling Pharma revealed plans to invest $22 million into innovative collaborations with other China pharmas; Tibet Pharma will go private at $3 per share; Cumberland Pharma of the US out-licensed the China rights for two of its drugs to Harbin Gloria Pharma; and Shanghai Pharma will collaborate with Guangdong Province’s CDC on cold chain drug distribution. More details….
Stock Symbols: (SHE: 002603) (NSDQ: TBET) (NSDQ: CPIX) (SHE: 002437) (SHA: 601607; HK: 02607)
